Copeptin as a biomarker and a diagnostic tool in the evaluation of patients with polyuria–polydipsia and hyponatremia. Issue 2 (March 2016)

• Record Type: Journal Article
• Authors: Christ-Crain, M.; Morgenthaler, N.G.; Fenske, W.
• Is Part Of: Best practice & research. Volume 30:Issue 2(2016)
• Page Start: 235
• Page End: 247
• Publication Date: 2016-03
• Subjects: arginine vasopressin -- copeptin -- polyuria–polydipsia syndrome -- diabetes insipidus -- hyponatremia; Endocrine glands -- Diseases -- Periodicals; Metabolism -- Disorders -- Periodicals; Endocrinology -- Periodicals; Metabolism -- Periodicals; 616.4
• DOI: 10.1016/j.beem.2016.02.003
• Languages: English
• ISSNs: 1521-690X

Abstract

Abstract : Copeptin is part of the 164 amino acid precursor protein preprovasopressin together with vasopressin and neurophysin II. During precursor processing, copeptin is released together with vasopressin. Copeptin concentrations respond as rapidly as vasopressin to changes in osmolality, a decrease in blood pressure or stress and there is a close correlation of vasopressin and copeptin concentrations. For these reasons, copeptin is propagated as a surrogate marker for vasopressin in the differential diagnosis of the polyuria–polydipsia syndromes and hyponatremia. Results of prospective studies show that a baseline copeptin level without prior fluid deprivation >20 pmol/L is able to identify patients with nephrogenic diabetes insipidus, whereas osmotically stimulated copeptin levels differentiate between patients with partial central diabetes insipidus and primary polydipsia with a high sensitivity and specificity >94%. In hyponatremia, low copeptin levels point to primary polydipsia and high levels to hypovolemic hyponatremia. The copeptin to urinary sodium ratio differentiates accurately between volume-depleted and normovolemic disorders.